Differential analyses of the proteomes in PL, CSF, and tumor samples, followed by FDR correction, revealed strong upregulation of CFHR2 (40.3-fold change) in the PL of patients with severe to profound hearing loss (hearing group 3) compared with patients with normal hearing or mild hearing loss (hearing group 1). This evidence concerns the gene CFHR2 and neoplasm.